Calibr-Skaggs and Kainomyx join forces to accelerate development of antimalarial drugs

The Calibr-Skaggs Institute for Innovative Medicines at Scripps Research and Kainomyx, Inc., today announced a new research collaboration to accelerate the discovery and development of next-generation antimalarial drugs.